Study analysis · Journal of the Endocrine Society · 2025
Half your weight loss on semaglutide isn't fat—it's muscle, and it could be hurting your blood sugar.
When people take semaglutide to lose weight, nearly half of what they lose is muscle, not fat—and that makes their blood sugar harder to control.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people who were already taking a weight-loss medicine or trying to lose weight with diet, and noticed that those who lost more muscle tended to be older, female, or ate less protein. But it didn’t make people take the medicine—it just watched what happened. So we can’t say the medicine caused the muscle loss, only that it happened together.
What’s the bottom line?
When people with obesity take semaglutide to lose weight, they often lose nearly half their weight as muscle and bone — not just fat.
How strong is this study?
This study tried to be careful by measuring muscle and blood sugar accurately, but it didn’t randomly assign people to groups, so the results might be skewed by other differences between the groups. That’s like noticing that kids who eat more candy get better grades—you can’t say candy helps grades if the smart kids just happened to like candy more.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
36 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=39)+3.5/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization, so it cannot establish cause-effect relationships due to potential confounding factors and selection bias.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors have financial relationships with pharmaceutical companies, including Novo Nordisk and Eli Lilly, whose products (e.g., semaglutide) are central to the study, raising concerns about potential bias in interpretation.
Conflict Details
BioAge: Financial relationship disclosed
Perspectum: Financial relationship disclosed
Lumos Pharma: Financial relationship disclosed
Recordati: Financial relationship disclosed
Novo Nordisk: Financial relationship disclosed
+27 more conflicts
Although no funding source is disclosed, multiple authors have financial ties to companies producing GLP-1 RAs (e.g., Novo Nordisk, Eli Lilly), which are the focus of the study. This creates a significant potential for bias in interpretation, especially given the study's conclusions about semaglutide's effects on muscle loss and glucose homeostasis. No safeguards for independent analysis are mentioned.
Key takeaways
- 01
Half (47.5%) of weight lost on semaglutide was muscle/bone; older people, women, and those eating less protein lost more muscle; more muscle loss meant worse blood sugar control.
- 02
Losing muscle while losing weight may make it harder to control blood sugar and could weaken bones over time, even if the scale goes down.
Surprising findings
- Semaglutide increased bone mineral density (BMD) while simultaneously increasing bone breakdown (CTX), with no change in bone formation (P1NP).People assume weight loss drugs weaken bones, but here BMD went up—yet the mechanism suggests dangerous bone remodeling. It’s like your bones are getting a cosmetic upgrade while the foundation rots.
- The link between total weight loss and muscle loss was much weaker with semaglutide (R=0.55) than with diet/lifestyle (R=0.93).With dieting, if you lose 10 lbs, you lose ~9 lbs of muscle. With semaglutide, you might lose 10 lbs and lose 2 lbs or 8 lbs of muscle—it’s unpredictable. The drug scrambles the body’s usual weight-loss pattern.
Practical takeaways
If you're on semaglutide, aim for 1.6–2.2g of protein per kg of body weight daily to protect muscle mass.
This study was small (n=39), observational, and only 3 months long—long-term effects and ideal protein levels need more research.
medium confidenceCombine semaglutide with resistance training 2–3x/week to counteract muscle loss and improve blood sugar control.
The study didn’t measure exercise—so while this is biologically sound, direct evidence from this trial is lacking.
medium confidenceAsk your doctor for a DXA scan before and after 3–6 months on semaglutide to track muscle and bone changes—not just weight.
DXA scans are expensive and not routinely ordered—access may be limited.
low confidenceWhy this study matters
47.5% of weight loss is muscle on semaglutide
In this study, people taking semaglutide lost 47.5% of their weight as lean mass (muscle and bone), compared to just 34.8% in those using diet and lifestyle changes alone. This means for every 10 pounds lost on semaglutide, nearly 5 pounds is muscle.
Most people think weight loss = fat loss, but this shows a popular weight-loss drug may be stripping away muscle—critical for metabolism, strength, and blood sugar control—without users realizing it.
Women and older adults lose more muscle
After adjusting for total weight loss, older age and female sex were independently linked to greater lean mass loss in semaglutide users—meaning women and older adults are at higher risk of muscle wasting on the drug.
This flips the script: the people most likely to benefit from weight loss (older adults, women with metabolic risks) are also the most vulnerable to its hidden downsides.
Low protein = more muscle loss
Lower protein intake at 3 months was strongly linked to greater lean mass loss in semaglutide users (R=0.52, p=0.02). Those eating more protein preserved more muscle.
It’s not just the drug—it’s what you eat with it. This gives viewers a simple, actionable lever to protect their muscle: eat more protein.
More muscle loss = worse blood sugar
Greater lean mass loss was independently tied to less improvement in HbA1c (p=0.03)—meaning losing muscle made blood sugar control worse, even if weight dropped.
This is the twist: you lose weight, but your diabetes risk doesn’t improve—and might even get worse—because you lost muscle. Muscle is where 80% of glucose gets burned.
Bones get denser—but are they stronger?
Semaglutide increased bone resorption (CTX rose 15%) and bone mineral density (BMD up 1.9%), but bone formation (P1NP) didn’t change. This suggests bones are being broken down and rebuilt unevenly.
Higher BMD sounds good—but if bone is being broken down faster than rebuilt, it could mean fragile bones long-term. It’s like painting over a crumbling wall.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When people with obesity take semaglutide to lose weight, they often lose nearly half their weight as muscle and bone — not just fat.
Research results
Half (47.5%) of weight lost on semaglutide was muscle/bone; older people, women, and those eating less protein lost more muscle; more muscle loss meant worse blood sugar control.
What this means - more context
Losing muscle while losing weight may make it harder to control blood sugar and could weaken bones over time, even if the scale goes down.
This study investigates predictors of lean mass loss and its metabolic consequences in adults with obesity treated with semaglutide versus diet/lifestyle intervention.
Among 39 adults with obesity, semaglutide users lost more weight and a higher proportion of lean mass (47.5%) than those on diet/lifestyle (34.8%). Greater lean mass loss with semaglutide was linked to older age, female sex, and lower protein intake, and independently associated with reduced HbA1c improvement. Semaglutide increased bone resorption (CTX) and BMD without changing bone formation (P1NP).
Methods Used
Prospective observational cohort study of 39 adults with obesity (22 on semaglutide, 17 on diet/lifestyle) over 3 months; lean mass measured by DXA; associations analyzed using correlation and adjusted regression models.
Main Finding
47.5% of weight loss with semaglutide was lean mass (vs. 34.8% with diet/lifestyle); greater lean mass loss with semaglutide was independently associated with older age, female sex, lower protein intake, and reduced HbA1c improvement (p=0.03).
Confidence Level
Moderate — small sample size (n=39), no randomization, and lack of confidence intervals limit reliability, but effect sizes and p-values are reported consistently.
Study Flags
Red Flags
- •Small sample size (n=39)
- •No randomization — groups not assigned randomly
- •No confidence intervals reported for effect sizes
Surprising Findings
Semaglutide increased bone mineral density (BMD) while simultaneously increasing bone breakdown (CTX), with no change in bone formation (P1NP).
People assume weight loss drugs weaken bones, but here BMD went up—yet the mechanism suggests dangerous bone remodeling. It’s like your bones are getting a cosmetic upgrade while the foundation rots.
Practical Takeaways
If you're on semaglutide, aim for 1.6–2.2g of protein per kg of body weight daily to protect muscle mass.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were already taking a weight-loss medicine or trying to lose weight with diet, and noticed that those who lost more muscle tended to be older, female, or ate less protein. But it didn’t make people take the medicine—it just watched what happened. So we can’t say the medicine caused the muscle loss, only that it happened together.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Prospective design with baseline and follow-up measurements
- Use of DXA for precise lean mass measurement
- Adjustment for weight change in multivariate analyses
Weaknesses
- No randomization between groups
- Blinding status unknown, risking detection bias
- Small sample size limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When people with obesity take semaglutide to lose weight, they often lose nearly half their weight as muscle and bone — not just fat.
Research results
Half (47.5%) of weight lost on semaglutide was muscle/bone; older people, women, and those eating less protein lost more muscle; more muscle loss meant worse blood sugar control.
What this means - more context
Losing muscle while losing weight may make it harder to control blood sugar and could weaken bones over time, even if the scale goes down.
This study investigates predictors of lean mass loss and its metabolic consequences in adults with obesity treated with semaglutide versus diet/lifestyle intervention.
Among 39 adults with obesity, semaglutide users lost more weight and a higher proportion of lean mass (47.5%) than those on diet/lifestyle (34.8%). Greater lean mass loss with semaglutide was linked to older age, female sex, and lower protein intake, and independently associated with reduced HbA1c improvement. Semaglutide increased bone resorption (CTX) and BMD without changing bone formation (P1NP).
Methods Used
Prospective observational cohort study of 39 adults with obesity (22 on semaglutide, 17 on diet/lifestyle) over 3 months; lean mass measured by DXA; associations analyzed using correlation and adjusted regression models.
Main Finding
47.5% of weight loss with semaglutide was lean mass (vs. 34.8% with diet/lifestyle); greater lean mass loss with semaglutide was independently associated with older age, female sex, lower protein intake, and reduced HbA1c improvement (p=0.03).
Confidence Level
Moderate — small sample size (n=39), no randomization, and lack of confidence intervals limit reliability, but effect sizes and p-values are reported consistently.
Study Flags
Red Flags
- •Small sample size (n=39)
- •No randomization — groups not assigned randomly
- •No confidence intervals reported for effect sizes
Surprising Findings
Semaglutide increased bone mineral density (BMD) while simultaneously increasing bone breakdown (CTX), with no change in bone formation (P1NP).
People assume weight loss drugs weaken bones, but here BMD went up—yet the mechanism suggests dangerous bone remodeling. It’s like your bones are getting a cosmetic upgrade while the foundation rots.
Practical Takeaways
If you're on semaglutide, aim for 1.6–2.2g of protein per kg of body weight daily to protect muscle mass.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were already taking a weight-loss medicine or trying to lose weight with diet, and noticed that those who lost more muscle tended to be older, female, or ate less protein. But it didn’t make people take the medicine—it just watched what happened. So we can’t say the medicine caused the muscle loss, only that it happened together.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Prospective design with baseline and follow-up measurements
- Use of DXA for precise lean mass measurement
- Adjustment for weight change in multivariate analyses
Weaknesses
- No randomization between groups
- Blinding status unknown, risking detection bias
- Small sample size limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study tried to be careful by measuring muscle and blood sugar accurately, but it didn’t randomly assign people to groups, so the results might be skewed by other differences between the groups. That’s like noticing that kids who eat more candy get better grades—you can’t say candy helps grades if the smart kids just happened to like candy more.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
36 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=39)+3.5/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization, so it cannot establish cause-effect relationships due to potential confounding factors and selection bias.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors have financial relationships with pharmaceutical companies, including Novo Nordisk and Eli Lilly, whose products (e.g., semaglutide) are central to the study, raising concerns about potential bias in interpretation.
Conflict Details
BioAge: Financial relationship disclosed
Perspectum: Financial relationship disclosed
Lumos Pharma: Financial relationship disclosed
Recordati: Financial relationship disclosed
Novo Nordisk: Financial relationship disclosed
+27 more conflicts
Although no funding source is disclosed, multiple authors have financial ties to companies producing GLP-1 RAs (e.g., Novo Nordisk, Eli Lilly), which are the focus of the study. This creates a significant potential for bias in interpretation, especially given the study's conclusions about semaglutide's effects on muscle loss and glucose homeostasis. No safeguards for independent analysis are mentioned.